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Preeclampsia is one of the leading causes of maternal and neonatal mortality and
morbidity worldwide, affecting 2–8% of all pregnancies. Studies suggest a link between
complement activation and preeclampsia. The complement system plays an essential
role in the innate immunity, leading to opsonization, inflammation, and elimination of
potential pathogens. The complement system also provides a link between innate and
adaptive immunity and clearance of immune complexes and apoptotic cells. During
pregnancy there is increased activity of the complement system systemically. However,
locally at the placenta, complement inhibition is crucial for the maintenance of a
normal pregnancy. Inappropriate or excessive activation of the complement system at
the placenta is likely involved in placental dysfunction, and is in turn associated with
pregnancy complications like preeclampsia. Therefore, modulation of the complement
system could be a potential therapeutic target to prevent pregnancy complications
such as preeclampsia. This review, based on a systematic literature search, gives
an overview of the complement system and its activation locally in the placenta and
systemically during healthy pregnancies and during complicated pregnancies, with a
focus on preeclampsia. Furthermore, this review describes results of animal and human
studies with a focus on the complement system in pregnancy, and the role of the
complement system in placental dysfunction. Various clinical and animal studies provide
evidence that dysregulation of the complement system is associated with placental
dysfunction and therefore with preeclampsia. Several drugs are used for prevention and
treatment of preeclampsia in humans and animal models, and some of these drugs
work through complement modulation. Therefore, this review further discusses these
studies examining pharmaceutical interventions as treatment for preeclampsia. These
observations will help direct research to generate new target options for prevention
and treatment of preeclampsia, which include direct and indirect modulation of the
complement system.
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INTRODUCTION
In pregnancy, protection of mother and fetus against potential
pathogens is essential, therefore a functional immune system
is required (1). Fetal tissues are directly exposed to the
maternal blood (2). Consequently, the maternal immune
system needs to tolerate these tissues to avoid potential
immune attacks at the feto-maternal interface (2, 3). In the
placenta, villous tissue covered by fetal trophoblast is in strict
connection with the maternal vascular system, where the
internal layer is formed by mononucleated cytotrophoblasts
and the external layer by multinucleated syncytiotrophoblast
(2). Extravillous trophoblast cells also invade the decidua
reaching the myometrium and the spiral arteries (2). The
endothelial cells of the spiral arteries are partly substituted by
endovascular (extravillous) trophoblasts (2). A healthy pregnancy
is associated with immunological changes, especially locally
at the feto-maternal interface, characterized by the presence
of uterine NK cells, and the induction of regulatory T cells
both essential for spiral artery remodeling, normal placental
development, and preventing fetal tissue rejections (4). The
complement system plays an important role in these processes
(1). It recruits and activates immune cells which leads to
opsonization, inflammation, and lysis of potential pathogens
(1, 2). Control of complement activation at the feto-maternal
interface is therefore important for a successful pregnancy, and
may otherwise lead to adverse pregnancy outcomes including
preeclampsia (3).
Preeclampsia is an important cause of maternal and neonatal
mortality and morbidity worldwide, affecting 2–8% of all
pregnancies (1). It is described by the development of endothelial
cell dysfunction, presenting as hypertension, and proteinuria
after 20 weeks of gestation (1, 3, 5). Preeclampsia, especially
when its onset is early in pregnancy, is associated with placental
dysfunction, reduced placental blood flow and fetal growth
restriction (FGR) (3). Also, the kidney develops severe damage
resulting in renal insufficiency, proteinuria, and abnormal renal
histology (5). The immune system is thought to play an
important role in the pathogenesis of preeclampsia, including
changes in the complement system (1). It is known that
activation of the complement system is involved in renal injury
in preeclampsia (5). Nowadays, the treatment of preeclampsia
is the delivery of the placenta and therefore also of the
fetus. Even though delivery is positive for the mother, it
may not be beneficial for the fetus, as it might be born
preterm (6).
In this review we will discuss various clinical and animal
studies providing evidence that dysregulation of the complement
system is associated with placental dysfunction and with
preeclampsia. Several drugs have been used as prevention
and treatment options for preeclampsia in human and animal
models, and some of these drugs possibly work through
complement modulation. Therefore, this review also discusses
these studies examining pharmaceutical interventions as
treatment for preeclampsia, with that we hope to help directing
research to generate new target options for prevention and
treatment of preeclampsia.
METHOD
For this review we aimed to provide an overview of the
complement system, and its activation locally in the placenta, and
systemically during normal healthy pregnancy, and complicated
pregnancies, focusing on preeclampsia. Therefore, we undertook
a systematic search of the published literature on animal and
human studies, which investigated the role of the complement
system in placental dysfunction, as it occurs in preeclampsia.
A list with articles was generated using combinations of the
following search terms in Pubmed: “placental dysfunction,
placental insufficiency, placenta, trophoblast, feto-maternal
interface, preeclampsia, pre-eclampsia, complement system,
complement activation, and complement”. Papers from this
list were selected on the basis of quality and relevance. Also,
we abstracted information on pharmaceutical interventions of
drugs which are currently used for prevention and treatment
of preeclampsia in humans and animal models, investigating
the role of complement modulation in these treatments of
preeclampsia. On the basis of these articles, we created
a perspective on the future prospects for targeting the
complement system in novel therapeutic strategies for treatment
of preeclampsia.
THE COMPLEMENT SYSTEM
The complement system consists of more than 30 proteins
present in the plasma and on cell surfaces (1, 7). When
the complement system is activated, it induces recruitment
and activation of immune cells resulting in opsonization,
inflammation and lysis of potential pathogens, immune
complexes, and apoptotic cells (Figure 1) (1, 7). The complement
system provides a linkage between innate and adaptive immunity
(7). Activation of the complement system can be achieved via
three pathways: the classical, alternative and lectin pathway (1, 7).
All pathways converge to create C3 convertases that split C3 into
its active components, C3a, and C3b (1). C3b binds covalently
to the activating surface of its target and also contributes to the
activation of a C5 convertase. C5 convertase cleaves C5 into C5a
and C5b. C5b then associates with C6, C7, C8, and C9 to form
the membrane-attack-complex (MAC; C5b-9), which cause lysis
(1, 2, 7). Anaphylatoxins, C3a, and C5a, induce chemotaxis and
release cytokines (1).
The fetal cells must avoid recognition and activation of the
complement system to achieve adequate trophoblast invasion
and healthy placentation (3, 8). Normal placentation is achieved
by local expression of regulators of the complement system, such
as DAF (CD55), CD59, and MCP (CD46), by inhibiting C3, and
C5 convertases, and the assembly of MAC on the membrane
surface (1–3). Complement components and regulators are
present at the placenta to provide immune protection and
also to favor implantation and placentation (3). C1q is
important in trophoblast migration and spiral artery remodeling,
contributing to normal placental development (1). Potential
complement activation occurs because of the development
of maternal antibodies, recognition of Pathogen-associated
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FIGURE 1 | Overview of the complement system. MAC, Membrane Attack Complex; MASPs, Mannose-associated Serine Proteases; MBL, Mannan-binding Lectin;
PAMP, Pathogen-associated Molecular Pattern.
Molecular Patterns (PAMPs) or spontaneous activation of the
system by exposure to villous structures (7). An excessive increase
of complement activation may damage invading extra villous
trophoblasts or placental syncytiotrophoblast and is associated
with adverse pregnancy outcomes, including preeclampsia (2, 9).
COMPLEMENT ACTIVATION AFTER
PREECLAMPSIA
Several human studies, as seen in Table 1, report an association
between placental deposition of complement factors and
dysregulation of placental function, particularly preeclampsia.
The number of patients in these studies is in general small.
Similarly, placental dysfunction is also seen in fetal growth
restriction (FGR), but human data on complement dysregulation
in this condition is even more scarce. Complement deposits can
be the consequence of either excessive activation or inadequate
regulation of the complement system (1, 9). Complement
activation is thought to be related to inflammatory events in
trophoblastic tissue, possibly subsequent to dysregulation of
placental angiogenesis (2).
Besides complement activation locally in placental tissue,
various studies explored complement activation in the circulation
of women with preeclampsia. Table 1 gives an overview of
several factors which are investigated, with different outcomes.
Inconsistency between studies could be the consequence of
differences in study populations, including pregnancy duration
(early-onset vs. late-onset), ethnicity, sample size, severity of the
disease, and method of analyzing circulating levels. Although
results are sometimes inconsistent, it is hypothesized that the
complement system is involved in preeclampsia (12–14, 17, 18).
Classical Pathway
Classical Pathway—Placenta
Modulation of the classical complement pathway in women with
preeclampsia was already observed in 1984. Higher deposition
Frontiers in Immunology | www.frontiersin.org 3 January 2020 | Volume 10 | Article 3098
Pierik et al. Complement Activation and Preeclampsia






Classical C1q - Higher deposition at chorionic villi; (10) PE n = 20, controls n = 20
- Lower deposition at the syncytiotrophoblast; (9) PE = 12, controls n = 8
- Higher deposition in controls and EOP compared to LOP in endothelia of
placental blood vessels; (9) EOP = 7, LOP n = 5, controls n = 8
- Comparable, deposition in syncytiotrophoblast and intravillous endothelial
cells; (11) PE n = 28, controls n = 30
- Lower levels; (12) PE n = 30, controls n = 30
C4bp - Higher percentage in controls compared to PE; (9) PE = 12, controls n = 8 N.a.
Lectin C4 N.a. - Lower levels; (13) PE n = 26, controls n = 25
(14) PE n = 88, controls n = 107
(12) PE n = 30, controls n = 30
C4d - Higher deposition in preterm PE with FGR compared to preterm PE
without FGR; (15) preterm PE-FGR n = 21, preterm PE n = 20
- Higher deposition at the syncytiotrophoblast and an association between
diffuse deposition in PE placentas and lower gestational age;
(11) PE n = 28, controls n = 30
- Higher deposition, as well in OD as in autologous pregnancies; (16)
OD+PE n = 9, non-donor PE n = 46, OD n = 33, IVF n = 20
- Higher levels; (17) PE n = 60, controls n = 60
(18) PE n = 60, controls n = 60
Ficolins (H, L) - High concentration, especially in the syncytiotrophoblast; (19) PE n = 5,
controls n = not specified, statistical analysis performed not specified
- Lower levels; (19) PE n = 20, controls n = 45
- L-ficolin: lower levels; (18) PE n = 60, controls n = 60
- H-ficolin: comparable levels; (18) PE n = 60, controls n = 60
MBL - Absent; (11) PE n = 28, controls n = 30 - Comparable levels; (19) PE n = 20, controls n = 45
- Higher median levels; (20) PE n = 99, controls n = 187
- MBL-MASP2: comparable levels; (21) PE n = 60,
controls n = 60
Alternative C3 - Higher deposition in the decidua of the basal plate and in the villi;
(22) PE n = 15, controls n = 13, no statistical analysis performed
- Higher deposition in decidual tissue; (23) PE n = 5, controls n = 5
- Higher deposition in the endothelial cells of villi; (24) PE n = 6,
controls n = 6
- Higher C3d deposition circumferentially on trophoblast basal membrane;
(10) PE n = 20, controls n = 20
- Comparable, deposition in syncytiotrophoblast layer and villous stroma;
(9) EOP n = 7, LOP n = 5, controls n = 10
- Comparable levels; (14) PE n = 88, controls n = 107 (25)
EOP n = 30, LOP = 78–80, controls n = 94–97
Fragment Bb N.a. - Higher levels; (26) severe PE n = 24, controls n = 20
- Higher levels in umbilical venous plasma; (26) severe PE n =
15, controls n = 15
- Early predictor of PE, 3 times more likely to develop PE (27)
Anaphylatoxins C3a - Lower C3aR mRNA and protein expression in Hofbauer cells in the villous
stroma in severe EOP; (28) severe EOP n = 19, controls n = 8
- Lower C3aR protein expression in severe PE; (29) severe PE n = 52,
controls n = 66
- Comparable levels; (30) cohort n = 668, PE n = 31, at 10–15
weeks of gestation
- Higher levels; (17) PE n = 60, controls n = 60
(18) PE n = 60, controls n = 60
(25) EOP n = 30, LOP = 78–80, controls n = 94–97
(29) severe PE n = 52, controls n = 66
- Higher levels in EOP compared to LOP; (25) EOP n = 30,
LOP = 78–80
C5a - Comparable, C5aR detected in syncytiotrophoblast and endothelial cells;
(28) severe EOP n = 19, controls n = 8
- Higher C5aR expression at trophoblast cells; (31) PE n = 6, controls n = 6
- Lower C5aR protein expression in severe PE; (29) severe PE n = 52,
controls n = 66
- Comparable levels; (12) PE n = 30, controls n = 30
- Higher levels; (29) severe PE n = 52, controls n = 66
MAC C5b-9 - More intense deposition, found in the decidua of the basal plate, in villous
stroma and in vessel walls; (22) PE n = 15, controls n = 13, no statistical
analysis performed
- Higher C9 deposition, circumferentially distributed; (10) PE n = 20,
controls n = 20
- Higher C9 deposition in severe PE compared to mild PE in villi; (10) severe
PE n = 10, mild PE n = 10
- Higher C9 deposition in villi; (32) PE n = 10, control n = 11
- Comparable, deposition in basal membrane of syncytiotrophoblast and in
villous stroma; (9) EOP n = 7, LOP n = 5, controls n = 10
- Comparable levels; (12) PE n = 30, controls n = 30
(30) cohort n = 668, PE n = 31, at 10–15 weeks of gestation
- Higher levels; (17) PE n = 60, controls n = 60
(18) PE n = 60, controls n = 60
(25) EOP n = 30, controls n = 94–97
- Higher levels PE-FGR compared to PE without FGR;
(17) n not specified
EOP, early-onset preeclampsia; FGR, fetal growth restriction; IVF, in vitro fertilization; LOP, late-onset preeclampsia; n, number; N.a., not available; OD, oocyte donation; PE, preeclampsia.
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of C1q at chorionic villi was observed in preeclamptic placental
tissues compared to normal pregnancy placental tissues (10).
At the syncytiotrophoblast layer, Lokki et al. overall observed
less C1q in preeclamptic patients compared with normal
controls (9). Noteworthy, C1q depositions were found in the
endothelial cells of placental blood vessels and the degree
of C1q deposition was significantly higher in controls and
early-onset preeclampsia group (EOP; <34 weeks) compared
to the late-onset preeclampsia group (LOP; ≥34 weeks) (9).
Also C4bp, an inhibitor of the classical pathway was found in
80% of the controls in the syncytiotrophoblast whereas 42%
of the preeclamptic placentas had some C4bp deposition in
the syncytiotrophoblast layer (9). In early-onset preeclampsia
typically more severe placental dysfunction is observed (9). On
the other hand, Buurma et al. did observe C1q deposition at
the syncytiotrophoblast and in intravillous endothelial cells in
preeclamptic and control placentas (11). In both case and control
groups, C1q was never entirely negative (11). Comparable results
were found regarding to the intensity and distribution of C1q
(11). To summarize, the results of C1q deposition varies, this
could be the case because studies focused on different parts of
the placenta, for example the fetal part or the vasculature of the
placenta. Also, a distinction between early-onset and late-onset
preeclampsia could explain the varying results. However, these
results encourage more research to understand the role of C1q in
the pathophysiology of preeclampsia.
According to Kim et al. there is a correlation between C4d
staining at the syncytiotrophoblast layer and maternal vascular
underperfusion (15). C4d immunoreactivity is significantly more
frequent in cases of preterm (<37 weeks) preeclampsia with FGR
than in preterm preeclampsia without FGR (15). Also, Buurma
et al. found significantly more C4d in preeclamptic placentas
compared to healthy controls, and found associations between a
diffuse deposition of placental C4d in preeclamptic women and
significantly lower gestational ages at delivery (11). According to
Buurma et al. the relation of placental C4d and lower gestational
age at birth implies that the degree of complement dysregulation
is related with the severity of preeclampsia (11). Remarkable,
Kim et al. found no association between C4d and the severity of
the disease in preeclampsia cases with and without FGR (15). It
is possible that C4d immunoreactivity is related with biological
challenges such as oxidative stress and endoplasmic reticulum
stress in placental cells (15). This could be the consequence of the
more severe forms of placental pathology resulting from shallow
placentation and resulting in ischemia-reperfusion injury (11,
15). C4d deposition may occur by activation of both the lectin
and classical pathway. It is suggested that C4d deposits are the
result of classical pathway activation, because C4d co-localized
with C1q (11, 33). Also, significantly higher C4d deposition
was observed in placentas after preeclampsia compared to
placentas after uncomplicated pregnancies, both in pregnancies
after oocyte donations, and autologous pregnancies (16).
Classical Pathway—Blood
Different studies showed altered complement activation of
the classical pathway, C1q, and C4, in peripheral blood in
preeclampsia (12–14, 17, 18). Significantly higher circulating
levels of C4d, a split product of C4, were observed in women
with preeclampsia compared to women with healthy pregnancies
(17, 18). Enhanced levels of C4d could be the result of activation
of the classical or lectin pathway (17). On the other hand,
studies also showed significantly lower circulating levels of C4 in
women with preeclampsia compared to normotensive controls
(13, 14). Agostinis et al. presented lower levels of C1q in
preeclamptic women compared to healthy controls, and also
observed a significant decrease in C4, suggesting an ongoing
activation of the classical pathway (12). They investigated if these
complement factors could be used as early predictive markers
of preeclampsia. Quantification of complement factors between
weeks 11 and 13 of gestation did not show significant differences
between the groups (12). Although C1q and C4 cannot be used
as early predictive markers of preeclampsia, it is shown that
preeclampsia is associated with altered complement activation
(12). It is possible that reduction of circulating levels of C4
as well as C1q are signals of consumption of complement
factors due to systemic activation of the immune response
(14). Consumption of complement factors is supported by
increased formation of split products, like increased deposition
and levels of C4d in preeclamptic placentas and circulation
compared to controls (14, 17). Another possible explanation is
that C1q is removed by binding to cells undergoing apoptosis




Focusing on the lectin pathway, ficolins (H, L) were differentially
expressed in plasma from preeclamptic pregnancies, compared to
healthy controls (19). Ficolins were found in low concentrations
in plasma but at high concentrations in the placenta, especially
in syncytiotrophoblast undergoing apoptosis when compared
with normal placentas (19). Increased trophoblastic apoptosis
stimulates placental and systemic innate immunity through
ficolin binding (19). The innate immune response can activate
the lectin-complement pathway to remove apoptotic cells (19).
Another activator of the lectin pathway, MBL, was absent in all
placentas (11).
Lectin Pathway—Blood
Different study groups measured levels in the circulation
of components of the lectin pathway during preeclampsia.
When studying MBL, women with preeclampsia have higher
median maternal plasma MBL concentrations than controls,
and high maternal plasma MBL concentrations were correlated
with preeclampsia (20). Also, a larger part of women with
preeclampsia have a high MBL concentration (>1898.9 ng/ml)
compared to controls, as well as a larger part of controls
have low/deficient (0–143.7 ng/ml) plasma MBL concentrations
than women with preeclampsia (20). Placental underperfusion
was noticed more frequent in patients with high plasma MBL
concentration, both in normal pregnant women and women
with preeclampsia (20). The exact role of the lectin pathway
in preeclampsia is not clear, but the high concentrations in the
Frontiers in Immunology | www.frontiersin.org 5 January 2020 | Volume 10 | Article 3098
Pierik et al. Complement Activation and Preeclampsia
maternal plasma reflect exaggerated intravascular inflammation,
and activation of the immune system in preeclampsia (20).
To determine the functional activity of MBL, Csuka et al.
studied the functional complex MBL-MASP2 (mannose-binding
lectin-associated serine protease 2) (21). MBL-MASP2 was
elevated in healthy pregnant women compared to non-
pregnant women (21). However, patients with preeclampsia
have comparable circulating levels of MBL-MASP2 as controls.
This demonstrates an activation of the lectin pathway during
pregnancy, but no further activation during preeclampsia was
demonstrated. So, in contrast to Than et al. and Csuka et al.
found no relation between the activity of the lectin pathway
and pathologic complement activation observed in preeclampsia,
suggesting a minor role of the lectin pathway in the development
of preeclampsia (20, 21). However, studying polymorphisms
in the MBL2 gene, fetal MBL2 haplotypes together with viral
exposure are linked to adverse pregnancy outcomes (34).
Ficolins activate the complement system through the lectin
pathway by association with effector MASPs (18). However,
there was no association between ficolin levels and complement
activation products (18). This suggests that the lectin pathway,
activated by ficolins, does not play an essential role in
complement activation during a healthy pregnancy, and
preeclampsia (18). Nevertheless, circulating levels of ficolin-
2 (L-ficolin) are decreased in the third trimester of normal
pregnancy compared to non-pregnant women (18). There is a
further significant reduction in plasma ficolin-2 concentrations
in preeclampsia compared to healthy non-pregnant and pregnant
women, due to its consumption or primary deficiency of
ficolin-2 (18). Women with preeclampsia showed an association
between plasma ficolin-2 concentrations and placental growth
factor (PIGF) concentrations and an inverse association with
serum levels of soluble fms-like tyrosine kinase-1 (sFlt-1)
(18). The decrease in ficolin-2 may therefore contribute to
the development of endothelial dysfunction and the maternal
features preeclampsia (18). Trophoblast apoptosis is normal
during pregnancy, but increased in preeclampsia, sometimes
dominated by necrosis (18). The underlying mechanism is the
ability of ficolins to function as direct opsonins and mediate
the clearance of among others apoptotic and necrotic cells
through phagocytosis (18). Due to consumption or primary
deficiency of ficolin-2 in plasma, it might influence the clearance
of apoptotic, and necrotic placental material, released into the




Tedesco et al. were one of the first who found C3 deposition in
preeclamptic placentas at the decidua of the basal plate and in the
stroma and basal membranes of the villi (22). Additional studies
(10, 23, 24) also observed an increase in C3 deposition after
immunostaining human placentas of preeclamptic pregnancies
compared to controls; however, Lokki et al. did not find a
difference (9). In contrast to the other studies, Lokki et al.
differentiated between early-onset and late-onset preeclampsia,
which might explain the conflicting results (9). Besides that,
it is also important to mention that some studies focused on
the maternal part of the placenta and others only on the fetal
part (9, 10, 22–24).
Alternative Pathway—Blood
Complement pathway activation fragment Bb functions as a
marker of alternative complement activation, mainly in the
circulation (26). In maternal plasma after more than 24 weeks
(blood drawn at 32.8 ± 4.4 weeks) of gestation, Bb levels
are higher in women with preeclampsia compared to controls
(26). Bb levels were significantly higher (nearly 2.5 times) in
umbilical venous cord plasma of preeclamptic subjects compared
to controls. In addition, there was a significant relation between
preeclamptic maternal and umbilical cord plasma Bb levels
(26). This may suggest an association between the alternative
complement pathway and preeclampsia (26). In contrast to C1q
and C4, fragment Bb can also be used in early pregnancy as a
predictor of preeclampsia (27). In a normal population, women
with elevated Bb (>90th percentile) before 20 weeks of gestation
are three times more presumably to develop preeclampsia than
women with lower levels (27). This also suggests an association
between fragment Bb and preeclampsia (27). Levels of C3 were
alsomeasured in the circulation of womenwith preeclampsia, but
these findings were comparable with control groups (14, 25).
Anaphylatoxins
Anaphylatoxins—Placenta
Anaphylatoxin C3a circulates in maternal blood and its action
is elicited via the C3a receptor (C3aR) (28). Lim et al.
found a decrease in C3aR mRNA expression in placental
tissue of severe early-onset preeclamptic women compared
to preterm control pregnancies, not affected by preeclampsia
(28). Additionally, C3aR protein expression was significantly
decreased in women with preeclampsia compared to controls
(28, 29). Decreased C3aR might indicate dysregulation of the
complement system, inciting inflammation. Whereby immune
complexes and necrotic cells are not appropriate lysed in
preeclamptic placentas (28) Lim et al. did not find any
differences in C5a receptor (C5aR) in contrast to Ma et al.
(28, 31) They detected an elevated C5aR expression at
trophoblast cells of preeclamptic placentas and suggested that
the placental C5a/C5aR pathway supported to the development
of preeclampsia by regulating placental trophoblasts dysfunction
(31). C5a stimulated trophoblasts toward an anti-angiogenic
phenotype by the increased expression of sFlt-1 and a decrease
in PIGF (31). A lower C5aR protein expression was found
in a larger study than Ma et al. and only focused on severe
preeclampsia compared to controls (29). This lower expression
might indicate an independent factor in the pathogenesis of
severe preeclampsia (29).
Anaphylatoxins—Blood
Anaphylatoxins C3a and C5a are often measured and altered
in women with preeclampsia compared to healthy pregnant
women. Although some studies did not find differences
between cases and controls (12, 30) other studies (17, 18, 25)
did demonstrate higher circulating levels of C3a in women
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with preeclampsia compared to controls. After differentiating
between early- and late-onset preeclampsia, C3a levels showed
a more pronounced elevation in the early than in the late
onset preeclampsia group (25). This suggests a different
pathophysiology of the two forms of preeclampsia and possibly
a more homogenous pathogenesis of the early onset form
compared to the late onset form (25). Also, Ye et al. found
higher C3a and C5a levels in women with severe preeclampsia
than in healthy pregnant women (29). They also showed
a positive correlation between C3a and C5a levels and a
maternal autoantibody AT1-AA, a potential contributor to the
pathogenesis of preeclampsia (29).
Terminal Pathway
Terminal Pathway—Placenta
Already in 1990 higher deposits of the membrane-attack
complex, C5b-9, were found in preeclamptic placentas compared
to normal placentas (22). Deposits of the terminal complex, C9,
were found in the basal membranes of the syncytiotrophoblast
and in villous stroma, but these deposits were comparable
between preeclampsia (early- and/or late-onset) and control
placentas (9). Other studies found in chorionic villi of
preeclamptic placentas higher C9 deposition compared to control
normal placentas (10, 32). More C9 deposition was found within
the fibrinoid parts. Besides that, these higher C9 depositions were
more present in placentas from severe forms of preeclampsia
than placentas from the mild form (10). These differences
could be explained by comparing subgroups with differences in
defining the subgroups. The study in question defined severe
preeclampsia as >2 g/l proteinuria and mild preeclampsia <2
g/l (10). Based on the weeks of gestation at diagnosis, early-
onset preeclampsia was indicated <34 weeks and late-onset >34
weeks of gestation (9). These results suggest a link between
preeclampsia and the activation of the complement system (22).
The terminal complement complex could be harmful to placental
tissue, through a direct lytic effect on cells or by promoting the
release of inflammatory products, which can lead to placental
dysfunction (22).
Terminal Pathway—Blood
The amount of terminal complex formation in preeclamptic
women compared to healthy pregnant women differs between
studies. Some studies did not find differences between
preeclamptic women and controls (12, 30), while several
others did (17, 18, 25). Lynch et al. collected blood of a cohort of
pregnant women between 10–15 weeks of gestation (30). In this
cohort comparable levels of sC5b-9 were found between women
who developed preeclampsia and women with a normotensive
pregnancy (30). Other studies included women at the time of
diagnoses of preeclampsia and mostly found higher levels of
sC5b-9 (17, 18, 25). Evidence have shown that preeclamptic
women with FGR have significantly higher plasma sC5b-9
levels than those without FGR (17). Besides that, there is a
correlation between C3 activation and enhanced terminal




Next to human studies on the complement system and
placental dysfunction, there are studies in mice and rats which
investigated the contribution of the complement system in
preeclampsia (Table 2). Different mouse or rat models have
been used to study placental dysfunction or preeclampsia
(Table 3). The animal models are used to mimic human like
preeclampsia characteristics and show a strong link with the
complement system.
Animal—Classical Pathway
Agostinis and colleagues examined the contribution the classical
pathway, via C1q, and pregnancy outcomes by analyzing
implantation sites from C1q−/− mice and controls (35). In C1q-
deficient mice, a higher fetal resorption frequency, decreased
fetal weight were observed at day 15 of pregnancy (35).
Histopathologic analysis of implantation sites from C1q−/−
mice showed signs of impaired placental development as
compared with controls, like diminished labyrinth development,
decreased vascular remodeling, and marked edema in the
interstitium of decidual stroma (35). A further study by Singh
et al. demonstrated also an association between the absence
of C1q, abnormal placentation, and onset of preeclampsia in
mice, characterized by hypertension, albuminuria, endotheliosis,
decreased vascular endothelial growth factor (VEGF), and
elevated levels of sFlt-1 (44).
Further research on the role of the classical pathway in
inducing fetal loss was reported by studying a risk factor of
developing preeclampsia (33). The complement system plays
a pivotal role in the antiphospholipid syndrome, but the
exact pathways are unknown. Therefore, pregnant control mice
and mice deficient in C1q and factor D were injected with
antiphospholipid antibodies (aPL) or control human IgG (33). In
the placentas of mice treated with aPL, increased C4 deposition
was observed, compared with placentas from normal human IgG
treated mice (33). C4 deposition was observed on trophoblast
giant cells, which are essential for implantation and invasion
of the conceptus into the uterus (33). There was a correlation
between C4 deposits and a higher fetal absorption rate (33).
Furthermore, mice deficient in C1q and factor D were protected
from aPL-induced fetal injury and no C4 deposition was
detected (33).
Animal—Lectin Pathway
The abortion-prone mouse mating combination of CBA/J x
DBA/2 is characterized by high fetal resorption and fetal growth
restriction (38). This model has been used to understand the role
of the complement system in recurrent pregnancy loss and fetal
growth restriction, but also shows similarities with preeclampsia
(38). This model demonstrates human preeclamptic features,
like elevated antiangiogenic factors, placental dysfunction,
and proteinuria, but no hypertension. In this mice model,
complement was activated primarily through the lectin pathway
(36). While only one form of MBL is present in humans, two
forms of MBL are found in mice, MBL-A and MBL-C (45).
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Classical C1q - Increased fetal resorption, reduced fetal weight and impaired
development of implantation sites (35)
- Abnormal placentation (reduced blood flow and increased
oxidative stress) and onset of PE in mice (hypertension,
albuminuria, endotheliosis, decreased VEGF and increased
levels of sFlt-1 (28)
- C1q deficient compared to wild-type C57BL/6 control mice
(35)
- C1q deficient compared to wild-type C57BL/6 control
mice (28)
Lectin C4 - Higher deposition on trophoblast and increased rate of fetal
resorption when injected with aPL (33)
- C1q and factor D deficient compared to wild-type C57BL/6
mice. Injected with aPL or control human IgG (33)
MBL-A - Localized at implantation sites, followed by higher C4, C3, and
C9 deposition. Absence of C1r in both groups (36)
- Lower C3 and C9 deposition and less fetal resorption in MBL-A
deficient mice (36)
- Abortion-prone CBA/J X DBA/2 compared to non-abortion-
prone control mice CBA/J X BALB/c (36)
- MBL-A−/− compared to MBL-A+/+ mice (36)
Alternative C3 - Increased deposition around the vasculature at E7.5 (37)
- Increased C3 together with C9 deposition in the TGC at E10.5
(37)
- AT1-AA mediated AT1-receptor activation contributed to
increased C3 deposition in the trophoblast and endothelial
cells (24)
- BPH/5 compared to C57BL/6 control mice (37)
- C57BL/6J mice; PE-IgG and NT-IgG (24)
Anaphylatoxins C3a - Signaling via C3aR is involved in hypertension, proteinuria,
sFlt-1, small placental sizes, impaired angiogenesis and
IUGR (24)
- C57BL/6J mice; PE-IgG compared to NT-IgG (24)
C5a - Increased C5a levels, related to a deficiency of VEGF and
increased levels of sFlt-1 (38)
- Abortion-prone mice CBA/J X DBA/2 compared to
non-abortion-prone control mice CBA/J X BALB/c (38)
aPL, antiphospholipid antibodies; AT1-AA, angiotensin II type 1 receptor agonistic autoantibody; BPH, blood pressure high; IUGR, intrauterine growth restriction; MBL, mannose-binding
lectin; NT, normo-tensive; PE, preeclampsia; s-Flt-1, soluble fms-like tyrosine kinase-1; TGC, trophoblast giant cell; VEGF, vascular endothelial growth factor.




High fetal resorption, fetal growth restriction and
defective vascularization and impaired development
of the placenta. Features of human preeclampsia:
proteinuria and glomerular endotheliosis, but no
hypertension (36, 38, 39)
Blood pressure high
(BPH/5) mice
Maternal features of preeclampsia and development
of placentopathies: shallow trophoblast invasion
and inadequate spiral artery remodeling (37, 40)
C1q−/− mice Deficient in C1q (classical pathway) (28, 35)
C1q and factor D deficient
mice
Deficient in C1q (classical pathway) and factor D
(alternative pathway) (33)




Placental ischemia is induced, resulting in reduction
of uteroplacental blood flow and hypertension
(41–43)
MBL-A was found at the implantation sites of these models. After
inhibition of MBL-A activity, MBL-A binding to the decidua was
inhibited, together with C3, and C9 deposition, and associated
with prevention of pregnancy loss (36, 38).
Animal—Complement Factor 3
Researchers studying complement factor 3, found increased
expression of C3 in vessels and placentas of preeclamptic
mice and rat models compared with controls, as seen in
Tables 2, 3. Preeclamptic animal models showed symptoms like
hypertension and proteinuria (14, 36, 37). Abnormal decidual
vasculature with excessive complement deposition was observed
around the vasculature in pregnant blood pressure high (BPH)/5
mice, which is a preeclampsia mouse model (37). There was
increased expression of C3 around the decidual vasculature of
E7.5 implantation sites and in the trophoblast giant cell layer
of E10.5 placentas (37). Also, C9 was significantly increased
in the trophoblast giant cell layer compared to controls,
suggesting activation of the final step of the complement cascade
and lysis of the opponent (37). They propose that aberrant
maternal (decidual) angiogenesis triggers complement activation
before placentation, leading to shallow endovascular trophoblast
invasion into the maternal spiral arteries, the first stage of
preeclampsia (37).
Wang et al. studied the contribution of AT1-AA to C3
elevation in placentas, by injecting IgG from normotensive
pregnant women or IgG from women with preeclampsia into
pregnant C57 mice (24). Immunohistochemical analysis revealed
that C3 was predominantly deposited in the placentas of mice
with injected IgG from preeclamptic women. Therefore, IgG
from preeclamptic women induces deposition of C3 in placentas
of pregnant mice via activation of the AT1-receptor (24).
Animal—Anaphylatoxins (C3a, C5a)
Wang et al. also examined C3aR expression using
immunohistochemistry (24). The C3a receptors were highly
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Classical sCR1 - Reduced C3a levels and reduced elevated MAP (41) RUPP compared to sham control rats (41)
Lectin CR2-FH - Comparable placental weights (4) BPH/5 compared to C57BL/6J control mice (40)
All pathways CR2-Crry - Increased placental weights (40)
- Inhibition of oxidative stress, proteinuria and placental
dysfunction (39)
BPH/5 compared to C57BL/6J control mice (40)
Abortion-prone CBA/J X DBA/2 compared to
non-abortion-prone control mice CBA/J X BALB/c (39)
Anapyhlatoxins C3a and/or C5a
antagonist
- Reduced increase in MAP, without altering the
decreased fetal weight or VEGF (42)
- C5a antagonists attenuated endothelial
dysfunction (42)
RUPP compared to sham control rats (41, 42)
Atrasentan - Improvement of hypertension (43)
- Comparable fetal and placental weights (43)
RUPP compared to sham control rats (43)
BPH, blood pressure high; MAP, mean arterial pressure; RUPP, reduced utero-placental perfusion pressure; VEGF, vascular endothelial growth factor.
expressed in trophoblast cells of mouse placentas. After blocking
C3aR, autoantibody-induced (AT1-AA) hypertension and
proteinuria in pregnant mice significantly improved (24). Also,
alterations in placenta histology and decreases in placental
and fetal weight were prevented, and serum levels of sFlt-1
were reduced (24). This implies a role for C3aR signaling in
autoantibody-induced abnormal placentas, FGR and impaired
placenta angiogenesis related to preeclampsia (24).
Excessive C5a generation is associated with impaired
angiogenesis using the abortion-prone CBA/J x DBA/2 mouse
mating combination, as mentioned before (38). The increased
C5a levels were related to a deficiency of VEGF and increased
levels of sFlt-1 (38). This suggests a relation between increased
circulating levels of anaphylatoxins and the pathophysiology
of preeclampsia.
INHIBITION OF THE COMPLEMENT
SYSTEM IN PREECLAMPTIC ANIMAL
MODELS
Therapeutic studies in animals prove the effect of inhibition of
the complement system in improving preeclampsia (Table 4).
Lillegard et al. used the reduced utero-placental perfusion
pressure (RUPP) rat model to induce hypertension in
the third trimester and studied the effect of decreasing
complement activation with a soluble recombinant form of
an endogenous complement regulator, human complement
receptor 1 (sCR1) (41). Compared to controls, preeclampsia
prone rats showed decreased circulating C3 and increased
C3a, indicating that complement activation has occurred.
sCR1 inhibited complement activation by reducing the
production of C3a and reducing the elevation of the mean
arterial pressure (MAP) (41). VEGF was also decreased in
RUPP rats compared to controls, but VEGF was not affected
by sCR1 treatment (41). So, sCR1 did not reverse RUPP-
induced FGR. This suggests that the role of complement in
placental ischemia-induced hypertension was independent
of VEGF (41).
Lillegard et al. further investigated the RUPP rat model
(42). They treated rats with C3aR or C5aR antagonists and
found a significant inhibition of the RUPP-induced increase
in MAP compared to controls (42). Treatment of rats with
a combination of both antagonists did not result in a better
MAP than treatment with one antagonist alone (42). Again,
VEGF did not change after treatment with C3aR and/or C5aR
antagonists (42). In addition, only C5aR antagonists attenuated
endothelial dysfunction followed by placental ischemia in the
RUPP model rats compared to controls (42). The mechanism
by which anaphylatoxins C3a and C5a contribute to placental
ischemia seems to be different (42).
In addition to the previous study, they hypothesized that
complement activation following placental ischemia leads to
activation of the endothelin pathway which triggers hypertension
and FGR (43). However, they suggested a complex interaction of
the endothelin and complement system in normal pregnancies
(43). After treatment with endothelin A receptor antagonist
atrasentan hypertension significantly improved, but fetal and
placental weight did not differ in the RUPP surgery groups
(43). Concerning the complement factors, circulating C3a was
increased in the RUPP surgery groups compared to controls,
but C3a was unaffected in the RUPP surgery groups after
treatment (43). Surprisingly, a significantly increased placental
C3 deposition was only observed in the control group after
treatment (43). This is explained by a significant downregulation
of normal complement regulators (CD55/Crry) in vivo placentas
by the endothelin antagonist (43).
Gelber et al. also studied the BPH/5 hypertensive mice
characterized by fetal loss and growth restriction in association
with abnormal placentation and defects in maternal decidual
arteries (40). They blocked all pathways of complement
activation with CR2-Crry and selectively inhibited the alternative
pathway with CR2-FH. Local complement inhibition was related
with increased weight of the placenta in the CR2-Crry treated
mice, but not in those treated with CR2-FH compared to controls
(40). Also, other researchers blocked complement activation at
the maternal-fetal interface by administering a single dose of
CR2-Crry in preeclamptic mice. Inhibition prevented among
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TABLE 5 | Overview of pharmaceutical interventions and their possible
mechanism improving preeclampsia.
Study Study design Drug Possible mechanism
improving preeclampsia
Bujold et al. (46)
Roberge et al. (47)
Meta-analysis Aspirin Improves trophoblastic
invasion of the uterine spiral
arteries. Down-regulates the
placental expression of C3 and
of complement factor B.
Rodger et al. (48)
Roberge et al. (49)
Wang et al. (50)
Meta-analysis Heparin Improves maternal vasculature,
endothelial function, increases
placental growth factor and
inhibits of C5a.











Lefkou et al. (6) Case-control Pravastatin Diminishes inflammation,
increases placental blood flow,
and reverses angiogenic and
redox imbalances. Inhibits
complement activation by
induction of DAF expression.
Sones et al. (52)
Reijnders et al. (53)
Case-control
(mice)
Celecoxib Increases uterine vascular
permeability and angiogenesis.
Does not significantly decrease
complement (C3, complement
factor B) expression in mice.
Burwick et al. (54) Case-report Eculizumab Inhibits C5, reduces C5a, and
C5b-9 generation.
others oxidative stress and placental dysfunction in these mice
compared to controls (39).
PHARMACEUTICAL INTERVENTIONS AS
PREVENTION OR TREATMENT OF
PREECLAMPSIA
Nowadays, treatment of preeclampsia is achieved by delivery
of the placenta and therefore of the fetus. Therapeutic
options are mostly symptomatic and not linked to underlying
causes. Currently, Low-dose Aspirin (LDA) + low-molecular-
weight heparin (LMWH) are the most common preventive
therapies for preeclampsia, but several studies have been
performed to investigate other potential therapies to postpone
delivery and protect mother and fetus (Table 5). Pharmaceutical
interventions as treatment or prevention for preeclampsia will
be discussed, the underlying mechanism and their link with the
complement system.
Drugs Investigated as Prevention for
Preeclampsia
Aspirin
Acetylsalicylic acid has both anti-inflammatory and antipyretic
effects. In a lower dose it inhibits platelet aggregation via
prostaglandin thromboxane A2. Several studies have investigated
the role of aspirin in preventing preeclampsia, with conflicting
results. A possible mechanism explaining that aspirin reduces
the risk of preeclampsia, is the improvement in trophoblastic
invasion of the uterine spiral arteries (46). Down-regulation of
placental expressions of complement factor 3 and factor B is
also suggested by LDA-treatment (55). A recent meta-analysis
examined the effect of aspirin in the prevention of preterm
and term preeclampsia in relation to gestational age at onset
of treatment and the dose of aspirin (47). They included 16
studies, also the large Combined Multimarker Screening and
Randomized Patient Treatment with Aspirin for Evidence-Based
Preeclampsia Prevention (ASPRE) trial, for a total of 18,907
participants between 1985 and 2017 (47, 56). Their conclusion,
aspirin starting at ≤16 weeks of gestation and at a dose of
≥100 mg/day decreases the risk of preterm preeclampsia by
approximately 70% (47). Aspirin did not reduce risk of term
preeclampsia (47). These findings were also suggested earlier in
a meta-analysis by Bujold et al. (46).
Heparin
Last years, clinical trials have studied the prevention of
preeclampsia by LMWH (50). The pathways by which LMWH
could prevent preeclampsia are not clear. Experiments have
demonstrated that LMWH exerts positive actions directly on the
maternal vasculature, endothelial function, increasing circulating
maternal levels of PIGF and inhibiting complement activation
(C5a) (57, 58). Overall, it is not clear if LMWH is capable of
suppressing one or various pathways that could contribute to
the development of preeclampsia (57). It might be that just
a subgroup of women at risk for early-onset preeclampsia-
associated placental and maternal cardiovascular dysfunction
may profit from LMWH, which may explain the conflicting trial
results (57, 58). Heparin has been found to influence complement
pathways in both in vitro and in vivo studies. It inhibits the effects
of complement pathways on the trophoblast; however especially
in mouse models of antiphospholipid syndrome (59).
The conclusions of the studies analyzing the use of a
LMWH as preventive therapy for preeclampsia are conflicting.
Rodger et al. performed an individual patient data meta-analysis
including 963 eligible women from eight trials (48). They noted
significant heterogeneity between single center and multicenter
trials and suggests that administration of LMWH does not have
an effect on the prevention of placenta-mediated pregnancy
complications, including preeclampsia (48). However, they also
suggest that additional large multicenter clinical studies are
needed (48). Furthermore, Wang et al. and Roberge et al.
performed a meta-analysis and compared LMWH plus LDA
with LDA only (49, 50). In addition, Wang et al. also included
two studies comparing a LMWH group with a no LDA group
and Roberge et al. also included unfractionated heparin. The
gestational ages of the enrolled women were all within 16 weeks
(50). Wang et al. and Roberge et al. found in, respectively seven
studies (1,035 participants) and eight studies (885 participants)
that LMWH effectively reduces the risk of preeclampsia in
pregnant women with a history of early onset or severe
preeclampsia (49, 50). Prophylactic use of LMWH prolongs
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gestational length and increases neonatal weight (50). Both
studies propose that there is a need for more larger multicenter
research, also including more screening indicators, for example
uterine artery Doppler ultrasound and serum markers (49, 50).
This will create more accurate screening of high-risk groups of
preeclampsia and will gainmore accurate and reliable evaluations
of the prevention efficacy of LMWH in these group of pregnant
women (49, 50).
Hydroxychloroquine
Hydroxychloroquine (HCQ), an antimalarial drug, is used in
the treatment of systemic lupus erythematosus (SLE) (51).
It is effective in preventing flares, achieving remission, and
reducing overall mortality (51). HCQ has several effects,
including antioxidant, anti-inflammatory, immunomodulatory,
and antithrombotic (51). It acts by impediment to lysosomal
function, interfering with antigen processing inmacrophages and
other antigen-presenting cells, inhibition of Toll-like receptors-
associated mechanisms thereby diminishing the production
of proinflammatory cytokines and also impair complement-
dependent antigen–antibody reactions (51, 60). Women with
SLE have a higher risk of developing preeclampsia than women
without SLE. This drug has been used in pregnant women with
SLE and it is also recommended to continue during pregnancy
for maintaining remission or to treat a flare (51). In 2019, Seo
et al. compared pregnancy outcomes, including preeclampsia, in
a retrospective study of SLE patients treated during pregnancy
with hydroxychloroquine (51). The incidence of preeclampsia
was significantly lower in the HCQ treatment group than in the
HCQ non-treatment group (51). Although the use of aspirin
during pregnancy was significantly higher in the HCQ treatment
group than in the HCQ non-treatment group, after correcting for
aspirin use, HCQ treatment group showed a lower incidence of
preeclampsia compared to the HCQ non-treatment group (51).
Despite the assumption that HCQ could inhibit the complement
system, levels of circulating C4 and C3 did not differ between
the groups. So its main effect will not exert via the complement
system (51).
Drugs Investigated as Treatment
for Preeclampsia
Pravastatin
Recently, Lefkou et al. assessed pregnancies outcomes in
women with antiphospholipid syndrome (APS) that developed
preeclampsia and/or FGR despit e the use of LDA+LMWH,
with additional pravastatin (HMG-CoA reductase inhibitor) (6).
At the time of the onset of placental insufficiency, pravastatin
was administered (6). Twenty-one pregnant women with APS
developed preeclampsia and/or FGR during treatment with LDA
+ LMWH (6). The control group (n = 10) received only
LDA+LMWH and 11 pregnant women received pravastatin
in addition to LDA+LMWH at the onset of preeclampsia
and/or FGR (6). The trial was unblinded. All control patients
delivered preterm by emergency C-section because of fetal
and/or maternal health concerns and three perinatal deaths were
observed. Pravastatin prolonged pregnancies significantly after
the onset of preeclampsia compared with those who did not
receive pravastatin. All patients with pravastatin delivered after
34 weeks with good neonatal outcomes and showed increased
placental blood flow and improvements in preeclampsia features
(6). Women who received pravastatin delivered close to term
(median, 36 weeks; IQR 35–36), which is beneficial for the
development of the fetus (6). This study analyzed the use of
pravastatin in pregnant women with APS at an increased risk
of adverse pregnancy outcomes (6). The mechanism of action
of pravastatin involves the complement system, by preventing
cervical remodeling and myometrial contractions (61). In mice
studies pravastatin inhibited complement activation (C5a) in
the cervix by increasing the production and expression of
complement inhibitor DAF (61).
Celecoxib
Celecoxib is a non-steroidal anti-inflammatory drug,
inhibits cyclooxygenase−2 (COX-2), and the production of
prostaglandins (PGE) (52). Implantation is important for
pregnancy outcome (52, 53). This is characterized by increased
uterine vascular permeability and angiogenesis and is under the
influence of among others COX-2 and prostaglandins (52, 53).
Sones et al. determined the effect of celecoxib in BPH/5 mice,
administered before placentation (52). They studied if angiogenic
factor imbalance and complement dysregulation improved after
therapy (52). They compared celecoxib-treated BPH/5 mice with
vehicle-treated BPH/5 and C57 mice controls. After a single dose
of a COX-2 inhibitor during pregnancy (E6.5) results showed
significant reduction in COX2 protein an PGE2 levels, improved
fetal growth, normalized placental weight, and diminished late
gestational hypertension in BPH/5 mice (52). Further study also
showed that celecoxib restores angiogenic factor expression at
the maternal-fetal interface in the BPH/5 mouse model (53).
Furthermore, placental complement expression after celecoxib
treatment showed an increase in C3 and complement factor
B mRNA in E10.5 placentas from control BPH/5 pregnancies
as compared with C57 vehicle-treated controls (53). However,
there were no differences in placental C3 and complement factor
B mRNA expressions between celecoxib-treated and vehicle-
treated BPH/5 pregnancies (53). These studies provided evidence
that decidual overexpression of COX-2 may trigger adverse
pregnancy outcomes seen in preeclampsia, although celecoxib
treatment is not sufficient to prevent aberrant complement
expression in BPH/5 placentas (52, 53).
Eculizumab
Eculizumab is a monoclonal antibody inhibitor of complement
factor 5 and decreases the generation of complement components
C5a and C5b-9 and inhibit their effects (54). A case report
described a patient presenting with severe preeclampsia/HELLP
syndrome at 26 weeks of gestation (54). After treatment
with Eculizumab (1,200mg) maternal and fetal status were
reassuring, laboratory parameters (LDH, haptoglobin, AST, ALT,
and platelet) improved and pregnancy was prolonged by 17
days (54). Maternal blood pressure fluctuated during treatment,
but eventually worsened to 140–160/90–100 mmHg together
with other laboratory parameters and delivery was advised
(54). However, complement proteins, angiogenic markers or
Frontiers in Immunology | www.frontiersin.org 11 January 2020 | Volume 10 | Article 3098
Pierik et al. Complement Activation and Preeclampsia
inflammatory cytokines were not measured (54). This report
describes the use of Eculizumab supports a possible benefit
for the treatment of preeclampsia by C5 inhibition. It
also suggests the involvement of the complement system in
preeclampsia. Therefore, it may be a treatment option for
preeclampsia (54).
Conclusion/ Future Perspectives
There is need for an effective therapy to treat or prevent
preeclampsia, because of the severe maternal and fetal
complications. Based on the discussed literature, there is
evidence that the complement system plays an essential role
in the pathogenesis of preeclampsia. The results of excessive
activation or inadequate regulation of the complement system
are increased circulating anaphylatoxins, increased deposition
of complement factors in the placenta and consumption of
circulating complement factors, leading to placental dysfunction.
Current therapy options are predominantly symptomatic and
might not intervene with the underlying pathophysiology of
preeclampsia. Modulation of the complement system deserves
attention, because data with pharmaceutical interventions to
investigate the complement system as a potential target to
treat preeclampsia are still scarce. In the future, studies are
needed to investigate the safety and efficacy of complement
modulation to treat or prevent preeclampsia. This can first
be done in animal experiments investigating the safety and
efficacy of complement modulation in preeclamptic models and
thereafter in clinical trials, at which safety of mother and fetus is
always paramount.
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